POCI — Precision Optics Corporation, Inc.

Precision Optics (POCI) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Q2 revenue reached a record $7.4 million, up 64% year-over-year (from $4.5 million) and up 10% sequentially (from $6.7 million).
• Production Revenue: Approximately $6.4 million, a 105% increase year-over-year (from $3.1 million) and a slight increase from $6.0 million in Q1.
• Engineering Revenue: $1 million, down 17% year-over-year (from $1.2 million) but up 43% sequentially (from $700,000).
• Gross Margin: 2.8%, significantly down from 14.2% in Q1 and 23.6% a year ago.
• Net Loss: $1.8 million, compared to a loss of $1.0 million in the prior year and $1.6 million in Q1.
• Adjusted EBITDA: Negative $1.5 million, worsening from negative $0.6 million year-over-year and negative $1.2 million in Q1.
• Cash Position: Approximately $900,000 in cash with $1.6 million in bank debt.

2. Strategic Updates and Business Highlights

• Production Programs: Continued strong performance in key programs, notably:
  • Aerospace program generated $2.7 million in revenue, with expectations to increase to over $3.5 million by Q4.
  • Single-use cystoscope program revenue increased to $2.0 million, with operational improvements expected to enhance margins.
• Operational Improvements: New COO Joe Traut has been instrumental in addressing production inefficiencies, leading to improved throughput and operational stability.
• Ross Optical Division: Revenue exceeded $1 million for the second consecutive quarter, with a strong backlog indicating a market rebound.
• Product Development: Increased bookings for engineering services, indicating a recovery in demand for product development.

3. Forward Guidance and Outlook

• Revenue Guidance: Increased to $26 million to $28 million for the fiscal year, up from the previous estimate of $25 million.
• Adjusted EBITDA Guidance: Revised to negative $2.5 million to negative $3.0 million, reflecting a shift in margin recovery expectations by one quarter.
• Expectations for Q3 and Q4: Anticipated strong improvement in Q3 and a return to positive adjusted EBITDA in Q4.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Decline: Significant drop in gross margins due to manufacturing inefficiencies, high scrap levels, and yield challenges, particularly in the cystoscope program.
• Negative Adjusted EBITDA: Continued losses in the first half of the fiscal year, pushing the timeline for profitability further out.
• Operational Growing Pains: The company has faced challenges in scaling production effectively, leading to resource constraints and inefficiencies.
• Dependence on Key Programs: The reliance on a few major production programs poses risks if demand fluctuates or operational issues persist.

5. Notable Q&A Insights

• Design Revisions: The company is implementing design changes to improve yields on the cystoscope line, with customer approval expected soon.
• Funding Discussions: Advanced negotiations for a new loan facility are underway, with potential grant funding from Massachusetts also being explored.
• Facility Updates: The company has completed updates to its headquarters and is planning further improvements to production facilities over the next 6 to 12 months.
• Long-Term Growth: Management expressed confidence in the long-term growth trajectory of the production business, supported by strong market demand for single-use medical devices and aerospace components.

Overall, while Precision Optics has shown impressive revenue growth and operational improvements, it faces significant challenges in gross margins and profitability that need to be addressed in the coming quarters.